TREK-1 in particular plays a central role in pain perception, neuroprotection, and cardiac rhythmogenesis (Alloui et al., 2006; Wiedmann et al., 2016; Lamas and Fernandez-Fernandez, 2019) and is considered a viable therapeutic target for treating depression (Heurteaux et al., 2006), atrial fibrillation (Lugenbiel et al., 2017), and hypermotility disorders of the gastrointestinal tract (Ma et al., 2018). Here, KCNK2 is linked to depressive symptom measurement.